These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 14635016)
21. Assessment of CMV load in solid organ transplant recipients by pp65 antigenemia and real-time quantitative DNA PCR assay: correlation with pp67 RNA detection. Mengoli C; Cusinato R; Biasolo MA; Cesaro S; Parolin C; Palù G J Med Virol; 2004 Sep; 74(1):78-84. PubMed ID: 15258972 [TBL] [Abstract][Full Text] [Related]
22. Human cytomegalovirus glycoprotein B genotypes in renal transplant recipients. Vogelberg C; Meyer-König U; Hufert FT; Kirste G; von Laer D J Med Virol; 1996 Sep; 50(1):31-4. PubMed ID: 8890038 [TBL] [Abstract][Full Text] [Related]
23. A prospective study comparing cytomegalovirus antigenemia, DNAemia and RNAemia tests in guiding pre-emptive therapy in thoracic organ transplant recipients. Lehto JT; Lemström K; Halme M; Lappalainen M; Lommi J; Sipponen J; Harjula A; Tukiainen P; Koskinen PK Transpl Int; 2005 Dec; 18(12):1318-27. PubMed ID: 16297050 [TBL] [Abstract][Full Text] [Related]
24. [Evaluation of viral load and antigenemia as markers for relapse cytomegalovirus infection in renal transplant recipients]. Franco A; Serrano R; Gimeno A; de Juan J; Merino E; Jiménez del Cerro L; Olivares J Nefrologia; 2007; 27(2):202-8. PubMed ID: 17564566 [TBL] [Abstract][Full Text] [Related]
25. New molecular assays to predict occurrence of cytomegalovirus disease in renal transplant recipients. Pellegrin I; Garrigue I; Ekouevi D; Couzi L; Merville P; Merel P; Chene G; Schrive MH; Trimoulet P; Lafon ME; Fleury H J Infect Dis; 2000 Jul; 182(1):36-42. PubMed ID: 10882579 [TBL] [Abstract][Full Text] [Related]
26. High prevalence of renal transplant recipients infected with more than one cytomegalovirus glycoprotein B genotype. Aquino VH; Figueiredo LT J Med Virol; 2000 May; 61(1):138-42. PubMed ID: 10745246 [TBL] [Abstract][Full Text] [Related]
27. High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function. Nickel P; Bold G; Presber F; Biti D; Babel N; Kreutzer S; Pratschke J; Schönemann C; Kern F; Volk HD; Reinke P Transpl Immunol; 2009 Mar; 20(4):238-42. PubMed ID: 19032982 [TBL] [Abstract][Full Text] [Related]
28. Cytomegalovirus replication and "herpesvirus burden" as risk factor of cardiovascular events in the first year after renal transplantation. Gómez E; Laurés A; Baltar JM; Melón S; Díez B; de Oña M Transplant Proc; 2005 Nov; 37(9):3760-3. PubMed ID: 16386530 [TBL] [Abstract][Full Text] [Related]
29. Identification of cytomegalovirus (CMV) infection by different laboratory methods in renal transplant recipients undergoing triple-drug immunosupressive treatment. Siennicka J; Durlik M; Litwińska B; Chmura A; Lewandowska D; Lao M; Paczek L; Kańtoch M Acta Microbiol Pol; 1999; 48(1):61-71. PubMed ID: 10467696 [TBL] [Abstract][Full Text] [Related]
32. Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection. Lilleri D; Fornara C; Chiesa A; Caldera D; Alessandrino EP; Gerna G Haematologica; 2008 Feb; 93(2):248-56. PubMed ID: 18245650 [TBL] [Abstract][Full Text] [Related]
33. Relationship of cytomegalovirus load assessed by real-time PCR to pp65 antigenemia in organ transplant recipients. Sanghavi SK; Abu-Elmagd K; Keightley MC; St George K; Lewandowski K; Boes SS; Bullotta A; Dare R; Lassak M; Husain S; Kwak EJ; Paterson DL; Rinaldo CR J Clin Virol; 2008 Aug; 42(4):335-42. PubMed ID: 18495527 [TBL] [Abstract][Full Text] [Related]
34. Human cytomegalovirus pp67 mRNAemia versus pp65 antigenemia for guiding preemptive therapy in heart and lung transplant recipients: a prospective, randomized, controlled, open-label trial. Gerna G; Baldanti F; Lilleri D; Parea M; Torsellini M; Castiglioni B; Vitulo P; Pellegrini C; Viganò M; Grossi P; Revello MG Transplantation; 2003 Apr; 75(7):1012-9. PubMed ID: 12698090 [TBL] [Abstract][Full Text] [Related]
35. Is combined pretransplantation seropositivity of kidney transplant recipients for cytomegalovirus antigens (pp150 and pp28) a predictor for protection against infection? Essa S; Pacsa A; Said T; Nampoory MR; Raghupathy R; Johny KV; Al-Nakib W; Al-Mosawy M Med Princ Pract; 2008; 17(1):66-70. PubMed ID: 18059104 [TBL] [Abstract][Full Text] [Related]
36. Differential detection of cytomegalovirus immediate-early messenger RNA in clinical samples using ligation-dependent PCR. Wu F; Li H; Zhang DY Mol Diagn; 2001 Dec; 6(4):233-9. PubMed ID: 11774188 [TBL] [Abstract][Full Text] [Related]
37. Comparison of cytomegalovirus pp-65 antigenemia assay and plasma DNA correlation with the clinical outcome in transplant recipients. de Oña M; Melón S; Galarraga MC; Palacio A; Lambert JL; Bernardo MJ; Rodríguez M; Gómez E Transpl Int; 2005 Jan; 18(1):43-6. PubMed ID: 15612982 [TBL] [Abstract][Full Text] [Related]
38. Cytomegalovirus (CMV) glycoprotein B genotypes and response to antiviral therapy, in solid-organ-transplant recipients with CMV disease. Humar A; Kumar D; Gilbert C; Boivin G J Infect Dis; 2003 Aug; 188(4):581-4. PubMed ID: 12898447 [TBL] [Abstract][Full Text] [Related]